Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Amicus Therapeutics (FOLD) Assets Average (2016 - 2025)

Historic Assets Average for Amicus Therapeutics (FOLD) over the last 17 years, with Q3 2025 value amounting to $842.1 million.

  • Amicus Therapeutics' Assets Average rose 963.99% to $842.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $842.1 million, marking a year-over-year increase of 963.99%. This contributed to the annual value of $781.5 million for FY2024, which is 405.22% up from last year.
  • Per Amicus Therapeutics' latest filing, its Assets Average stood at $842.1 million for Q3 2025, which was up 963.99% from $802.6 million recorded in Q2 2025.
  • Amicus Therapeutics' Assets Average's 5-year high stood at $930.9 million during Q4 2021, with a 5-year trough of $712.3 million in Q1 2023.
  • Its 5-year average for Assets Average is $793.1 million, with a median of $785.8 million in 2024.
  • In the last 5 years, Amicus Therapeutics' Assets Average soared by 1091.3% in 2021 and then crashed by 2030.92% in 2022.
  • Over the past 5 years, Amicus Therapeutics' Assets Average (Quarter) stood at $930.9 million in 2021, then decreased by 20.31% to $741.8 million in 2022, then increased by 3.93% to $771.0 million in 2023, then increased by 1.92% to $785.8 million in 2024, then increased by 7.16% to $842.1 million in 2025.
  • Its Assets Average stands at $842.1 million for Q3 2025, versus $802.6 million for Q2 2025 and $787.4 million for Q1 2025.